Equities

Jack Chia Industries Thailand PCL

Jack Chia Industries Thailand PCL

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (THB)79.00
  • Today's Change0.00 / 0.00%
  • Shares traded1.00k
  • 1 Year change+0.64%
  • Beta--
Data delayed at least 15 minutes, as of May 03 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Jack Chia Industries (Thailand) Public Company Limited is a Thailand-based company. The Company is principally engaged in the manufacture and distribution of pharmaceutical products and cosmetics. The Company operates through two segments. The manufacture and distribution of pharmaceutical products. The manufacture and distribution of other consumer products. The Company’s brands include Tigerplast, Tensoplast, Kangaroo, Tabu, Thermaplast, Jason, Ronson and Golden lion. The Company offers various products under Tigerplast brand, such as Tigerplast Extra Comfort Knee Support, Tigerplast Extra Comfort Ankle Support, Tigerplast Extra Comfort Wrist Support and others. The Company offers various products under Tabu brand, such as Tabu Shower Cream, Tabu Soap, Tabu Perfumed Talcum, Klear After Shave By Tabu and Klear Ice Cologne By Tabu. The Company’s subsidiaries include Pharmacare Limited and JCT new frontiers holdings Limited.

  • Revenue in THB (TTM)885.75m
  • Net income in THB95.13m
  • Incorporated1966
  • Employees136.00
  • Location
    Jack Chia Industries Thailand PCL114/1 Soi Chalongkrung 31Lumplatew, Ladkrabang,BANGKOK 10520ThailandTHA
  • Phone+66 22360036
  • Fax+66 22361379
  • Websitehttps://www.jackchia.co.th/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Immuno-Biological Laboratories Co., Ltd.189.21m-46.27m1.03bn60.00--3.90--5.44-20.69-20.6984.62118.020.51440.87883.7813,135,280.00-12.58-15.11-14.85-17.6162.0656.66-24.45-50.043.490.4940.1774--22.710.9405-11.97------
Cynata Therapeutics Ltd10.59m-331.29m1.05bn0.00--3.51--98.82-0.0873-0.08730.00270.06830.0257--4.26---80.33-38.07-87.15-41.10-----3,127.93-513.73----0.00---94.9619.81-162.20------
Renascience Inc45.93m-79.62m1.07bn3.00--2.70--23.19-26.09-26.0915.05129.220.0851----63,772,000.00-14.74---15.49--85.75---173.36------0.1782---27.84---32.05------
Jack Chia Industries Thailand PCL885.75m95.13m1.07bn136.0011.210.7929.311.207.057.0565.6199.740.55852.174.246,512,870.006.005.616.666.0841.3141.1510.7410.154.00--0.0064.5018.301.517.591.19-9.910.237
Bafna Pharmaceuticals Ltd675.35m49.62m1.09bn588.0021.18--14.961.614.934.9365.88--------2,607,335.00--0.228--0.363630.5334.367.350.3193--4.72----35.6019.60117.36--130.43--
MEDRx Co Ltd7.09m-223.96m1.11bn22.00--2.25--155.89-27.24-27.240.849250.170.01710.26061.221,342,455.00-54.07-58.15-58.45-62.2391.8795.70-3,158.72-1,526.1717.75--0.00---50.3528.6016.04---55.29--
Inoviq Ltd18.25m-158.06m1.11bn85.00--2.72--60.61-0.0708-0.07080.00820.1820.03392.100.873---29.33-47.68-32.18-50.7695.07---866.27-2,527.824.93--0.0332--119.59153.3150.71------
Data as of May 03 2024. Currency figures normalised to Jack Chia Industries Thailand PCL's reporting currency: Thai Baht THB
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.